RCMNY
RVNC

Rubric Capital Management (New York)’s Revance Therapeutics, Inc. RVNC Stock Holding History

Rubric Capital Management (New York)’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,656,847
Closed -$6.83M – 77
2024
Q2 		$6.83M Hold
2,656,847
– – 0.18% 58
2024
Q1 		$13.1M Buy
2,656,847
+1,195,373
+82% +$7.08M 0.39% 54
2023
Q4 		$12.8M Sell
1,461,474
-138,526
-9% -$1.13M 0.27% 45
2023
Q3 		$18.4M Buy
+1,600,000
New +$30.8M 0.69% 37

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

Rubric Capital Management (New York)'s RVNC Position: Q3 2024 in Review

Rubric Capital Management (New York) sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2024, closing a stake of 2,656,847 shares — an estimated $6.83M sold.

Rubric Capital Management (New York) first reported a position in RVNC in Q3 2023 and held it in 4 quarters. The position peaked at $18.4M in Q3 2023. 201 funds tracked by Wall St. Rank hold RVNC as of Q3 2024.

  • Rubric Capital Management (New York) reported no remaining Revance Therapeutics, Inc. position as of Q3 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 2,656,847 Revance Therapeutics, Inc. shares in Q3 2024, an estimated $6.83M.
  • Rubric Capital Management (New York) first reported a position in Revance Therapeutics, Inc. in Q3 2023 and held it in 4 quarters.
  • Rubric Capital Management (New York)'s Revance Therapeutics, Inc. position peaked at $18.4M in Q3 2023.
  • 201 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2024, filed 13 Nov 2024.